Get the Stockscreener App
0.70
18.45%
-0.1584
After Hours:
.70
Accelerate Diagnostics Inc stock is traded at $0.70, with a volume of 138.47K.
It is down -18.45% in the last 24 hours and down -35.19% over the past month.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
See More
Previous Close:
$0.8584
Open:
$0.855
24h Volume:
138.47K
Relative Volume:
2.97
Market Cap:
$17.53M
Revenue:
$12.00M
Net Income/Loss:
$-63.23M
P/E Ratio:
-0.1167
EPS:
-6
Net Cash Flow:
$-43.02M
1W Performance:
-33.96%
1M Performance:
-35.19%
6M Performance:
-60.23%
1Y Performance:
-29.29%
1-Day Range:
$0.688
$0.88
1-Week Range:
$0.688
$1.15
52-Week Range:
$0.688
$2.09
Accelerate Diagnostics Inc Stock (AXDX) Company Profile
Name
Accelerate Diagnostics Inc
Sector
Industry
Phone
303-863-8088
Address
3950 S. COUNTRY CLUB ROAD #470, TUCSON, AZ
Compare AXDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXDX
Accelerate Diagnostics Inc
|
0.70 | 17.53M | 12.00M | -63.23M | -43.02M | -6.00 |
|
ABT
Abbott Laboratories
|
130.82 | 226.88B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
99.36 | 146.96B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
364.50 | 142.81B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
87.63 | 112.37B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.85B | 5.72B | 4.17B | 259.90M | 6.97 |
Accelerate Diagnostics Inc Stock (AXDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-22 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-08-20 | Initiated | BTIG Research | Neutral |
| Aug-07-20 | Upgrade | Craig Hallum | Hold → Buy |
| Sep-27-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-18 | Initiated | Craig Hallum | Hold |
| Dec-13-17 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-12-17 | Resumed | BTIG Research | Buy |
| Mar-24-16 | Initiated | JP Morgan | Overweight |
| Dec-16-15 | Initiated | Piper Jaffray | Overweight |
View All
Accelerate Diagnostics Inc Stock (AXDX) Latest News
AXDX stock touches 52-week low at $0.73 amid market challenges By Investing.com - Investing.com South Africa
AXDX stock touches 52-week low at $0.73 amid market challenges - Investing.com Australia
Accelerate Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com - Defense World
Accelerate Diagnostics Reports 2024 Financial Results - TipRanks
Antimicrobial Susceptibility Testing Market Expecting Huge Demand in Upcoming Years Accelerate Diagnostics - openPR
Accelerate Diagnostics Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
Accelerate Diagnostics seeks FDA clearance for WAVE system By Investing.com - Investing.com Australia
Accelerate Diagnostics seeks FDA clearance for WAVE system - Investing.com India
InventHelp Inventor Develops Modified Single-Serve Coffeemaker (KXK-162) - The Malaysian Reserve
Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance - PR Newswire
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results - PR Newswire
Accelerate Diagnostics Inc. (AXDX) reports earnings - Quartz
Accelerate Diagnostics, Inc SEC 10-K Report - TradingView
Accelerate Diagnostics (AXDX) Expected to Announce Quarterly Earnings on Thursday - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Major Microbial Identification Market Trend 2025-2034: Automated Systems Transform Microbial Identification... - WhaTech
Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Accelerate Diagnostics CFO Patience David sells $583 in stock By Investing.com - Investing.com South Africa
Investor Network: Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics CFO Patience David sells $583 in stock - Investing.com
Merger Agreement with BioSymetrics to Accelerate Biomarker Identification, Enhance Drug Discovery and Expand Precision Medicine Applications in Advanced Cancer Diagnosis and Treatment | FinancialContent Business Page - Financial Content
Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine - The Manila Times
Renovaro and BioSymetrics Announce Definitive Merger - GlobeNewswire
Masimo (MASI) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Armenian Reporter
Axos Invest Inc. Purchases 54,293 Shares of Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) - Armenian Reporter
Antimicrobial Susceptibility Testing Market Advancements Highlighted by Analysis and Forecast to 2033: Mark... - WhaTech
Indaba Capital Management, L.P. Acquires Significant Stake in Ac - GuruFocus.com
BD to separate biosciences and diagnostics business - BioWorld Online
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Projected to Reach USD 6.5 Billion by 2035 at a 4.2% of CAGR | Future Market Insights, Inc. - Morningstar
Global Antimicrobial Resistance Surveillance Market to Reach USD 9.50 Billion by 2032, Growing at a CAGR of 5.47% - WICZ
Accelerate Diagnostics faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
Accelerate Diagnostics faces Nasdaq delisting risk - Investing.com
Global Antimicrobial Susceptibility Testing Market to Reach USD 4.8 Billion by 2035, Growing at a CAGR of 3.6% | Future Market Insights, Inc. - GlobeNewswire Inc.
Accelerate Diagnostics (NASDAQ:AXDX) Share Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Accelerate Diagnostics reports preliminary FY 2024 revenue of $11.7 million - MSN
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results - PR Newswire
Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test - Business Wire
GRIFFIN ASSET MANAGEMENT, INC. Reduces Holdings in Accelerate Di - GuruFocus.com
Aptitude Secures $10M+ to Accelerate Development of Point-of-Care and Over-the-Counter CT/NG/TV STI Test on Metrix® Platform - PR Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update - Defense World
Accelerate Diagnostics Inc Stock (AXDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):